Irish Life Investment Managers’s Neurocrine Biosciences NBIX Stock Holding History

Irish Life Investment Managers’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q2	$62K	Buy	+4,635	New	+$56.9K	﹤0.01%	1212

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VHCP Management New York $93M AUM 10.04% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Irish Life Investment Managers's NBIX Position: Q2 2013 in Review

Irish Life Investment Managers opened a new position in Neurocrine Biosciences (NBIX) in Q2 2013: 4,635 shares worth $62K. The stake represents ﹤0.01% of the portfolio and ranks #1212 among its holdings.

126 funds tracked by Wall St. Rank hold NBIX as of Q2 2013.

Irish Life Investment Managers held 4,635 shares of Neurocrine Biosciences worth $62K as of Q2 2013.
Neurocrine Biosciences was a new Irish Life Investment Managers position in Q2 2013.
Neurocrine Biosciences made up ﹤0.01% of Irish Life Investment Managers's portfolio in Q2 2013, its #1212 holding.
126 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2013.

Based on Irish Life Investment Managers's 13F filing for Q2 2013, filed 13 Aug 2013.